Navigation Links
Facial Injectables Emerge From the Recession
Date:11/30/2009

WALTHAM, Mass., Nov. 30 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the nearly $1.2 billion global facial injectable market declined by almost 5% over 2008 as patients chose to delay or forego treatment as a result of the economic crisis. The market will, however, begin recovery in 2010, and by 2014, will return to the strong pre-recession growth rates of over 15%. MRG's facial injectable series, which includes separate reports on North America, Europe, Asia Pacific, and Latin America, finds that many manufacturers are refining marketing strategies and strengthening product portfolios in order to establish optimal market position in the coming years.

To combat financial pressures and bolster share in advance of economic recovery, some firms that had longstanding plans to enter the US market were granted FDA approval and launched new products in 2009 in hopes of stimulating interest and adoption amongst new practitioners and patients. In the US, notable releases included the highly anticipated Dysport by Ipsen and Medicis Pharmaceutical, and the approval of Sculptra Aesthetic by sanofi-aventis. In the European facial injectable market, Ipsen and Galderma launched Azzalure, a version of Dysport that is rebranded for aesthetic use in Europe. Although these competitors launched their products during difficult financial times, the interest stimulated through these launches will carry through into recovery, positioning the firms favorably for improved cosmetic procedure volumes.

"The launch of these new products has generated a lot of media attention, owing in part to the extensive marketing campaigns and promotional activities that manufacturers are engaging in," says Lisa Shantz, Analyst at MRG. "Although these newly-introduced products will have a greater impact when the market begins to recover in 2010, many physicians and patients are now much more aware of the different types and brands of products at their disposal. As new manufacturers continue to enter the market, competitive pricing pressures will make treatments increasingly affordable for patients, spurring procedure volume growth."

MRG's global facial injectable series examines how the botulinum toxin, hyaluronic acid dermal filler, particle and polymer filler, and collagen filler markets were affected by the recession and just how quickly they will return to healthier growth rates. Each report includes detailed, segmented analyses of procedures by product type, unit sales, average selling prices, market revenues, and competitor shares. The North American facial injectable report also segments injections by the area of the face in which the products are injected.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:

Amy Krohn
Millennium Research Group
416-364-7776 ext. 101
akrohn@mrg.net

Elizabeth Marshall
Decision Resources Inc.
781-296-2563
emarshall@dresources.com

SOURCE Millennium Research Group


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Promising Results in Treating Facial Bruising From Injectables
2. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
3. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
4. Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
5. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
6. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
7. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
10. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
11. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Company, Inc. (NYSE MKT: AXN) today announced that for the ... the Company achieved revenue of $8,195,839, a 27% improvement on ... 2015. --> --> The ... $2,068,635, or $.03 per share, up 265% from the net ... of fiscal year 2015. Gross margin for the three months ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... A man who has struggled to quit smoking, a man who has struggled with hair ... solutions to his problems – and he did. Now Nabat, a serial entrepreneur featured as ... breakthrough inventions to the world and better people's lives. His own experience with nicotine addiction ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running and ... companies. Attendees also get to see the most incredible gardens and home improvement ... , at the Colorado Convention Center - 700 14th St. Denver CO, is an ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua ... on how healthcare companies can use newly released government data on populations and ... population and intervene and capture the value they create to succeed in new ...
Breaking Medicine News(10 mins):